Literature DB >> 3974172

Effects of the beta 2-adrenoceptor agonists fenoterol and salbutamol on force of contraction in isolated human ventricular myocardium.

A Mügge, D Posselt, U Reimer, W Schmitz, H Scholz.   

Abstract

The effects of fenoterol and salbutamol on isometric force of contraction were studied in isolated, electrically driven human papillary muscle preparations. Fenoterol increased force of contraction at concentrations of 1 mumol l-1 and higher. The maximally effective concentration of fenoterol (100 mumol l-1) increased force of contraction by about 130%. The positive inotropic effect of fenoterol was not influenced by 0.1 mumol l-1 prazosin. The beta 1-selective antagonist atenolol (2 mumol l-1) and the beta 2-selective antagonist ICI 118551 (1 mumol l-1) shifted the concentration-response curve of fenoterol to the right, indicating that beta 1- and beta 2-adrenoceptors may contribute to the positive inotropic effect of fenoterol. In contrast to fenoterol, salbutamol increased force of contraction only by about 11% at 100 mumol l-1. The results indicate that: (1) fenoterol exerts a direct positive inotropic effect in the human heart which may support the beneficial effects of the reduction of systemic vascular resistance in patients with congestive heart failure; (2) this positive inotropic effect of fenoterol is mediated by beta 1- and beta 2-adrenoceptors; (3) the clinically observed improvement of cardiac performance in the case of salbutamol is presumably not due to any direct positive inotropic effect.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3974172

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  28 in total

1.  The pharmacology of atenolol.

Authors:  A M Barrett
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

2.  A selective beta-adrenoreceptor stimulant (Th1165a) related to orciprenaline.

Authors:  S R O'Donnell
Journal:  Eur J Pharmacol       Date:  1970-09-01       Impact factor: 4.432

3.  Salbutamol and orciprenaline-induced changes in myocardial function.

Authors:  W G Nayler; I McInnes
Journal:  Cardiovasc Res       Date:  1972-11       Impact factor: 10.787

4.  Clinical studies with beta 2 adrenoceptor agonists in heart failure.

Authors:  J R Dawson; J Bayliss; M S Norell; R Canepa-Anson; P Kuan; S Reuben; P A Poole-Wilson; G C Sutton
Journal:  Eur Heart J       Date:  1982-12       Impact factor: 29.983

5.  The human heart beta-adrenergic receptors. II. Coupling of beta 2-adrenergic receptors with the adenylate cyclase system.

Authors:  M Waelbroeck; G Taton; M Delhaye; P Chatelain; J C Camus; R Pochet; J L Leclerc; J M De Smet; P Robberecht; J Christophe
Journal:  Mol Pharmacol       Date:  1983-09       Impact factor: 4.436

6.  Beta-adrenoceptors of the human myocardium: determination of beta 1 and beta 2 subtypes by radioligand binding.

Authors:  A Heitz; J Schwartz; J Velly
Journal:  Br J Pharmacol       Date:  1983-12       Impact factor: 8.739

7.  Evidence that ICI 118, 551 is a potent, highly Beta 2-selective adrenoceptor antagonist and can be used to characterize Beta-adrenoceptor populations in tissues.

Authors:  S R O'Donnell; J C Wanstall
Journal:  Life Sci       Date:  1980-08-25       Impact factor: 5.037

8.  The importance of choice of agonist in studies designed to predict beta 2 : beta 1 adrenoceptor selectivity of antagonists from pA2 values on guinea-pig trachea and atria.

Authors:  S R O'Donnell; J C Wanstall
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-09       Impact factor: 3.000

Review 9.  Fenoterol: a review of its pharmacological properties and therapeutic efficacy in asthma.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-01       Impact factor: 9.546

10.  Coexistence of beta 1- and beta 2-adrenoceptors in human right atrium. Direct identification by (+/-)-[125I]iodocyanopindolol binding.

Authors:  O E Brodde; K Karad; H R Zerkowski; N Rohm; J C Reidemeister
Journal:  Circ Res       Date:  1983-12       Impact factor: 17.367

View more
  15 in total

1.  Characterization and autoradiographic localization of beta-adrenoceptor subtypes in human cardiac tissues.

Authors:  B F Buxton; C R Jones; P Molenaar; R J Summers
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

2.  Electrophysiological effects mediated by the stimulation of cardiac beta 2-adrenoceptors with tulobuterol.

Authors:  A Mugelli; S Amerini; P De Bonfioli Cavalcabo; E Cerbai; S Visentin
Journal:  Cardiovasc Drugs Ther       Date:  1987       Impact factor: 3.727

Review 3.  Dose-response of inhaled drugs in asthma. An update.

Authors:  D J Clark; B J Lipworth
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

4.  Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients.

Authors:  B J Lipworth; D M Newnham; R A Clark; D P Dhillon; J H Winter; D G McDevitt
Journal:  Thorax       Date:  1995-01       Impact factor: 9.139

5.  Cardiac ventricular beta 2-adrenoceptors in guinea-pigs and rats are localized on the coronary endothelium.

Authors:  M Freissmuth; V Hausleithner; S Nees; M Böck; W Schütz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-09       Impact factor: 3.000

Review 6.  β₂ AR agonists in treatment of chronic heart failure: long path to translation.

Authors:  Mark I Talan; Ismayil Ahmet; Riu-Ping Xiao; Edward G Lakatta
Journal:  J Mol Cell Cardiol       Date:  2010-10-01       Impact factor: 5.000

7.  Inhibition by fenoterol of human eosinophil functions including beta2-adrenoceptor-independent actions.

Authors:  A Tachibana; M Kato; H Kimura; T Fujiu; M Suzuki; A Morikawa
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

8.  Beta 2-adrenoceptor-mediated positive inotropic effect of adrenaline in human ventricular myocardium. Quantitative discrepancies with binding and adenylate cyclase stimulation.

Authors:  A J Kaumann; H Lemoine
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-04       Impact factor: 3.000

9.  Reduced alpha 1- and beta 2-adrenoceptor-mediated positive inotropic effects in human end-stage heart failure.

Authors:  M Steinfath; W Danielsen; H von der Leyen; U Mende; W Meyer; J Neumann; M Nose; T Reich; W Schmitz; H Scholz
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

10.  Contribution of beta 1- and beta 2-adrenoceptors of human atrium and ventricle to the effects of noradrenaline and adrenaline as assessed with (-)-atenolol.

Authors:  H Lemoine; H Schönell; A J Kaumann
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.